Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Last trade$144.56
Day change+$0.53 (+0.37%)
Day range$141.15 – $149.00
Volume1,222,801
Market cap$19.49B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$19.49B
Price / earnings
—
Price / book
-70.62×
Price / sales
15.24×
EV / sales
15.61×
EV / EBITDA
-42.94×
Profitability
Earnings per share
-$3.59
Return on assets
-25.72%
Return on equity
175.81%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-5.45×
Current ratio
3.6×
Quick ratio
3.35×
Cash ratio
2.75×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$232.15M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GH, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$360.98M
$334.98M
$301.67M
$281.27M
$265.2M
$232.09M
$203.47M
$201.81M
Cost of revenue
$124.82M
$115.95M
$104.92M
$99.49M
$93.59M
$81.21M
$74.72M
$77.59M
Gross profit
$236.15M
$219.03M
$196.75M
$181.77M
$171.61M
$150.88M
$128.75M
$124.22M
Selling, general and administrative
$268.08M
$251.61M
$227.06M
$204.32M
$180.64M
$169.85M
$151.27M
$156.64M
Research and development
$100.84M
$96.53M
$91.04M
$98.26M
$89.96M
$87.45M
$88.52M
$93.54M
Total operating expenses
$368.92M
$348.15M
$318.1M
$302.58M
$270.6M
$257.3M
$239.79M
$250.19M
Operating income
-$132.77M
-$129.12M
-$121.35M
-$120.81M
-$98.99M
-$106.41M
-$111.04M
-$125.97M
Interest expense
-$1.35M
-$1.35M
-$1.35M
-$1.18M
-$943K
-$983K
-$791K
-$645K
Income before taxes
-$124.02M
-$119.96M
-$111.7M
-$130.22M
-$92.59M
-$99.86M
-$94.87M
-$110.29M
Income taxes
$343K
$185K
$372K
-$1.73M
$136K
$38K
$290K
$716K
Net income
-$124.36M
-$120.14M
-$112.08M
-$128.49M
-$92.73M
-$99.9M
-$95.16M
-$111.01M
Net income attributable to common shareholders
-$124.36M
-$120.14M
-$112.08M
-$128.49M
-$92.73M
-$99.9M
-$95.16M
-$111.01M
EBITDA
-$122.59M
-$119.56M
-$111.91M
-$110.76M
-$89.58M
-$96.37M
-$100.81M
-$115.51M
Basic earnings per share
-$0.93
-$0.90
-$0.85
-$1.00
-$0.74
-$0.80
-$0.77
-$0.90
Diluted earnings per share
-$0.93
-$0.90
-$0.85
-$1.00
-$0.74
-$0.80
-$0.77
-$0.90
Recent news
Company coverage with links to the original publishers.
Guardant Health reported a quarterly loss of $0.29 per share, matching consensus estimates and improving from a $0.39 loss a year ago. The company exceeded revenue expectations with $360.98 million, up from $265.2 million year-over-year. The stock has gained 65.1% since the beginning of the year, significantly outperforming the S&P 500's 12.3% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Guardant Health reported Q3 2026 revenue of $360.98 million, beating Wall Street estimates by 2.89% with 36.1% year-over-year growth. The company posted an EPS of -$0.29, matching consensus estimates. Key metrics showed strong performance across screening tests (83,000 vs. 72,322 estimate) and oncology revenue (+25.4% YoY), though biopharma revenue slightly missed expectations. The stock holds a Zacks Rank #3 (Hold) rating.
CRISPR Therapeutics is expected to report Q3 2026 results with a consensus EPS loss of $1.06 per share and revenues of $9.95 million (up 1018% YoY). With a positive Earnings ESP of +0.11% and Zacks Rank #3, the company is positioned as a likely earnings-beat candidate. The stock previously beat estimates by 14.55% in the last quarter.
The article explains how to use the Zacks Earnings ESP (Expected Surprise Prediction) filter to identify stocks likely to beat earnings expectations. The ESP compares the most accurate analyst estimate to the consensus estimate, and when combined with a Zacks Rank #3 or better, stocks posted positive surprises 70% of the time with average annual returns of 28%. Two medical stocks highlighted as examples are Humana (HUM) with a #2 Buy rating and +3.33% ESP, and Guardant Health (GH) with a #3 Hold rating and +4.76% ESP.
Guardant Health is expected to report Q3 2026 earnings on November 5 with a consensus loss of $0.29 per share and revenues of $350.83 million (up 32.3% YoY). The company has a positive Earnings ESP of +4.76% combined with a Zacks Rank #3, suggesting it will likely beat consensus estimates. However, recent estimate revisions have been 6.86% lower over the last 30 days.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.